PF 277343
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alopecia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Alopecia in USA
- 20 Dec 2006 Phase-I clinical trials in Alopecia in USA (unspecified route)